Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer

Table 2 RAF, MEK and PI3K/mTOR inhibitors presently in the status of clinical trial in colorectal cancer

Drug	Target	Manufacturer	Phase	Indication
Sorafenib	BRAF	Bayer	II	Colon cancer (combination with cetuximab)
PLX4032	BRAFV600E	Plexxikon	I	Melanoma, colon cancer
XL281	BRAF	Exelixis	I	Solid tumors
GSK1120212	MEK	GlaxoSmithKline	I	Solid tumors, Lymphoma
AZD6244	MEK	AstraZeneca	II	Colon cancer (combination with capecitabine)
AS703026	MEK	EMD Serono	I	Solid tumors
GDC-0973	MEK	Genentech	I	Solid tumors
RO5126766	MEK	Hoffman-La Roche	I	Solid tumors
TAK-733	MEK	Millenium	I	Solid tumors
RDEA119	MEK	Ardea Biosciences	I	Solid tumors
BGT226	PI3K	Novartis	I/II	Solid tumors, Her2 positive Breast Cancer
XL147	PI3K	Exelixis	I	Solid tumors, Lymphoma
XL765	PI3K	Exelixis	I	Solid tumors
BEZ235	PI3K	Novartis	I	Solid tumors
GDC-0941	PI3K	Genentech	I	Solid tumors
PX-866	PI3K	ProIX	I	Solid tumors
SF1126	PI3K	Semafore	I	Solid tumors
Everolimus	mTOR	Novartis	II	Colon cancer (combination with cetuximab)